Estia Health Limited (ASX: EHE) – Earnings for FY18 in line with guidance

Australia’s leading aged care provider, Estia Health Limited (ASX: EHE) today, as at 16 August 2018, reported 4.1% increase in FY18 EBITDA to $90.1 million which is in line with earnings growth guidance.

Net profit of the company increased by 1.1% to $41.2 million on the back of average occupancy of 94.2% and operating revenue growth of 4.3% to $547.1 million. Estia financial results for the year ending 30 June 2018 indicated the stabilization in care services business notwithstanding the higher wage cost, and unfavorable change in government laws, among other challenges.

[optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

Departing Chief Executive officer of Estia Health, Norah Barlow stated that the company had successfully maintained the earnings before interest tax depreciation and amortization margin despite having staff cost pressure during the year.

The group has opened two new homes which include Twin Waters in Queensland and Kogarah in New South Wales, adding to the building capacity of the company with 136 new beds over the past 12 months.

The company declared fully franked final dividend of 8 cents per security, representing a 100% payout of Net Profit After Tax for the period. The dividend is scheduled for payment on 28 September 2018 with a record date of 7 September 2018.

In relation to the recent announcement of CEO and COO succession, Estia’s Chief Executive Officer Norah Barlow confirmed the seamless transition on her stepping down in November 2018 and Ian Thorley, Deputy CEO, advancing to the role of CEO. The company expects investment of up to $115 million on the outlook for FY19. It also forecasts mid-single digit percentage growth in EBITDA on its existing portfolio.

Following FY18 results announcement, EHE stock plunged by 0.946% to $3.140 on 16 August 2018.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report